Accelerator based epithermal neutron source

Taskaev, S. Yu.

doi:10.1134/s1063779615060064

Cited by 61 publications

(39 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As for its use on the territory of the Russian Federation, it is planned to build a clinic for BNCT in collaboration with the Budker Institute of Nuclear Physics using a tandem accelerator characterized by a proton beam current of 9 mA and an energy of 2.3 MeV [10]. To gain the necessary proton beam, a new type of particle accelerator has been proposed and built -a tandem accelerator with vacuum insulation.…”

Section: F I G U R Ementioning

confidence: 99%

“…BNCT is based on nuclear capture and 10 B(n, α) 7 Li fission reactions [11]. 10 B atoms capture the thermal neutrons and instantly decay to produce an alpha particle ( 4 He), a recoiled lithium nucleus ( 7 Li), and low linear energy transfer (LET) γ radiation ( Figure 1). 10 B isotope atoms absorb low-energy thermal neutrons (< 0.5 eV), resulting in the reaction: 10 B + n → 7 Li + 4 He, wherein alpha particles acquire the high-LET, ≈150 keV/μm, 7 Li ion, ≈175 keV/μm [12].…”

Section: Physical Basesmentioning

confidence: 99%

“…10 B atoms capture the thermal neutrons and instantly decay to produce an alpha particle ( 4 He), a recoiled lithium nucleus ( 7 Li), and low linear energy transfer (LET) γ radiation ( Figure 1). 10 B isotope atoms absorb low-energy thermal neutrons (< 0.5 eV), resulting in the reaction: 10 B + n → 7 Li + 4 He, wherein alpha particles acquire the high-LET, ≈150 keV/μm, 7 Li ion, ≈175 keV/μm [12]. A feature of these particles is that they provide a high energy along their very brief pathway (< 10 μm), which is comparable to the diameter of one cell.…”

Section: Physical Basesmentioning

confidence: 99%

See 2 more Smart Citations

Boron neutron capture therapy: Current status and future perspectives

Дымова

Taskaev

Richter

et al. 2020

Cancer Communications

175

173

View full text Add to dashboard Cite

The development of new accelerators has given a new impetus to the development of new drugs and treatment technologies using boron neutron capture therapy (BNCT). We analyzed the current status and future directions of BNCT for cancer treatment, as well as the main issues related to its introduction. This review highlights the principles of BNCT and the key milestones in its development: new boron delivery drugs and different types of charged particle accelerators are described; several important aspects of BNCT implementation are discussed. BCNT could be used alone or in combination with chemotherapy and radiotherapy, and it is evaluated in light of the outlined issues. For the speedy implementation of BCNT in medical practice, it is necessary to develop more selective boron delivery agents and to generate an epithermal neutron beam with definite characteristics. Pharmacological companies and research laboratories should have access to accelerators for large‐scale screening of new, more specific boron delivery agents.

show abstract

Section: F I G U R Ementioning

confidence: 99%

Section: Physical Basesmentioning

confidence: 99%

Section: Physical Basesmentioning

confidence: 99%

See 1 more Smart Citation

Boron neutron capture therapy: Current status and future perspectives

Дымова

Taskaev

Richter

et al. 2020

Cancer Communications

175

173

View full text Add to dashboard Cite

show abstract

“…The studies were carried out on a tandem accelerator with vacuum insulation [3] that generates a proton beam with an energy of 2 MeV, a current up to 5 mA, and a transverse dimension of about 1 cm [12]. Figure 1 shows an image of the experimental apparatus.…”

Section: Experimental Apparatusmentioning

confidence: 99%

“…To enable the development of a promising cancer therapy, boron neutron capture therapy [1,2], an accelerator-based epithermal neutron source was designed and made at the Budker Institute of Nuclear Physics [3,4]. Neutrons are generated as a result of a 7 Li(p,n) 7 Be threshold reaction by directing a proton beam, with an energy of 2 MeV and a current of up to 5 mA obtained in a tandem accelerator with vacuum insulation, to a lithium target with a diameter of 10 cm.…”

Section: Introductionmentioning

confidence: 99%

In Situ Observations of Blistering of a Metal Irradiated with 2-MeV Protons

Badrutdinov

Bykov

Gromilov

et al. 2017

Metals

View full text Add to dashboard Cite

A vacuum-insulated tandem accelerator was used to observe in situ blistering during 2-MeV proton irradiation of metallic samples to a fluence of up to 6.7 × 10 20 cm −2 . Samples consisting of copper of different purity, tantalum and tantalum-copper compounds were placed on the proton beam path and forced to cool. The surface state of the samples was observed using a charge-coupled device camera with a remote microscope. Thermistors, a pyrometer and an infrared camera were applied to measure the temperature of the samples during irradiation. After irradiation, the samples were analyzed on an X-ray diffractometer, laser and electron microscopes. The present study describes the experiment, presents the results obtained and notes their relevance and significance in the development of a lithium target for an accelerator-based neutron source, for use in boron neutron capture therapy of cancer.

show abstract

Advances of LINAC-based boron neutron capture therapy in Korea

Bae¹,

Kim²,

Seo³

et al. 2022

AAPPS Bull.

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) has been attracting interest as a new radiation modality for cancer therapy because it can selectively destroy cancer cells while maintaining the healthy state of surrounding normal cells. Many experimental trials have demonstrated significant BNCT treatment efficacy using neutron beams from research reactors. However, nuclear reactor technology cannot be scaled to sites in hospitals delivering patient treatment. Therefore, compact accelerator-based neutron sources that could be installed in many hospitals are under development or have even been commissioned at many facilities around the world. In Korea, a radio-frequency (RF) linac-based BNCT (A-BNCT) facility is under development by DawonMedax (DM). It provides the highly efficient production of an epithermal neutron beam with an optimized neutron energy spectrum range of 0.1~10 keV. With a 2-mA 10-MeV proton beam from the accelerator, the irradiation port epithermal neutron flux is higher than 1 × 109 n/cm2⋅s. Comprehensive verification and validation of the system have been conducted with the measurement of both proton and neutron beam characteristics. Significant therapeutic effects from BNCT have been confirmed by DM in both in vitro and in vivo non-clinical trials. Further, during exposure to epithermal neutrons, all other unintended radiation is controlled to levels meeting International Atomic Energy Agency (IAEA) recommendations. Recently, the Korean FDA has accepted an investigational new drug (IND) and the first-in-human clinical trial of BNCT is now being prepared. This paper introduces the principles of BNCT and accelerator-based neutron sources for BNCT and reports the recent advances of DM A-BNCT facility which is the main part of this paper.

show abstract

Accelerator based epithermal neutron source

Cited by 61 publications

References 109 publications

Boron neutron capture therapy: Current status and future perspectives

Boron neutron capture therapy: Current status and future perspectives

In Situ Observations of Blistering of a Metal Irradiated with 2-MeV Protons

Advances of LINAC-based boron neutron capture therapy in Korea

Contact Info

Product

Resources

About